EUCTR2015-005210-30-LV进行中（未招募）1 期
Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.A 52-week randomised, double-blind, active- and placebo-controlled trial - PIONEER 4
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 690
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
- •2. Male or female, age above or equal to 18 years at the time of signing informed consent. For Japan only: Male or female, age = 20 years at the time of signing informed consent.
- •3. Diagnosed with type 2 diabetes mellitus = 90 days prior to day of screening.
- •4. HbA1c of 7.0–9.5 % (53–80.3 mmol/mol) (both inclusive).
- •5. Stable daily dose of metformin (=1500 mg or maximum tolerated dose as documented in the subject medical record) alone or in combination with a stable daily dose of a SGLT-2 inhibitor for at least 90 days prior to day of screening (fixed-dose combinations are allowed).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 517
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 173
排除标准
- •1. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice). For certain specific countries: Additional specific requirements apply.
- •2. Any disorder, which in the investigator’s opinion might jeopardise subject’s safety or compliance with the protocol.
- •3. Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary Thyroid Carcinoma (MTC).
- •4. History of pancreatitis (acute or chronic).
- •5. History of major surgical procedures involving the stomach and potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).
- •6. Any of the following: myocardial infarction (MI), stroke or hospitalisation for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening.
- •7. Subjects presently classified as being in New York Heart Association (NYHA) Class IV.
- •8. Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.
- •9. Subjects with ALT > 2.5 × upper normal limit (UNL).
- •10. Renal impairment defined as estimated Glomerular Filtration Rate (eGFR) < 60 mL/min/1.73 m^2 as per Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI).
- •11. Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before the day of screening. An exception is short-term insulin treatment for acute illness for a total of =14 days.
- •12. Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or dilated fundoscopy performed within 90 days prior to randomisation.
- •13. History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and carcinoma in situ).
- •14. History of diabetic ketoacidosis.
研究者
相似试验
进行中（未招募）
1 期
Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.Diabetes Mellitus, Type 2MedDRA version: 19.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2015-005210-30-HUovo Nordisk A/S690
进行中（未招募）
1 期
Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.Diabetes Mellitus, Type 2EUCTR2015-005210-30-DEovo Nordisk A/S690
进行中（未招募）
1 期
Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.Diabetes Mellitus, Type 2MedDRA version: 20.0 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000072461EUCTR2015-005210-30-CZovo Nordisk A/S711
进行中（未招募）
1 期
Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.Diabetes Mellitus, Type 2EUCTR2015-005210-30-HRovo Nordisk A/S690
进行中（未招募）
1 期
Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.Diabetes Mellitus, Type 2EUCTR2015-005210-30-SKovo Nordisk A/S690